NEW YORK – Parsippany, New Jersey-based Interpace Diagnostics announced today that it has signed a contract with Blue Cross Blue Shield of Michigan to cover its ThyGeNext and ThyraMir thyroid cancer detection assays as an in-network service, limiting the insurer's members' out-of-pocket expenses.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account? Login Now.
This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.
This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.